Abstract Library

#1775 Potential Therapeutic Targets for Gastric Poorly Differentiated Neuroendocrine Carcinoma

Introduction: Gastric poorly differentiated neuroendocrine carcinoma (G-PDNEC) is rare and aggressive. Patients often present with distant metastases at initial diagnosis.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: JI Y

Authors: Ji Y, Xie Y, Chen K, Zeng H, Sun Y,

Keywords: gastric, neuroendocrine carcinoma, mTOR pathway, SSTR, targeted therapies,

#1307 Expression of m-TOR Pathway Components in Gastric Neuroendocrine Neoplasms: A Pilot Study

Introduction: The mammalian target of rapamycin (mTOR) signaling pathway plays a key role in the regulation of cell proliferation, protein synthesis and neuroendocrine tumor growth.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Delektorskaya V, Peregorodiev I, Bokhian V, Stilidi I,

Keywords: neuroendocrine, neoplasm, gastric, immunohistochemistry ,

#1221 Pancreatic Location, High Proliferation and Low p-mTOR Expression Levels Are More Frequent in Neuroendocrine Tumor Patients Responsive to mTOR Inhibitors: Results from a Preliminary Study

Introduction: MTOR inhibitors are approved for the treatment of advanced neuroendocrine tumors. However, scarce data are available on clinical or pathological predictors of response to these agents

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Volante M

Authors: Birocco N, Brizzi M, Airoldi M, De Angelis C, Ciuffreda L,

Keywords: mTOR inhibitor, biomarker,

#898 Evaluation of Tumor Response to Targeted Therapies in Precision-Cut Slices of Human Pancreatic Neuroendocrine Tumors

Introduction: Patients with PNET might benefit from new therapeutic approaches acting on the mTOR signaling pathway. Culture of precision-cut slices could allow testing these molecules in human tumors, allowing personalized treatments.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Bucau M, Cros J, Rebours V, Albuquerque M, Paradis V,

Keywords: pancreas, targeted therapies, tissue culture, neuroendocrine tumors,

#592 Expression of PTEN and mTOR in Pancreatic Neuroendocrine Tumors and Their Clinical Significance

Introduction: mTOR is currently under investigation as a potential target for anticancer therapy. Loss of PTEN, the negative regulators of the PI3K-Akt-mTOR pathway, have been associated with cancer.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Han X, Ji Y, Zhao J, Xu X, Lou W,

Keywords: pNET, mTOR, PTEN, ICH, clinical behavior, prognosis,